Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 9,917 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

NCT02075463
View directory record Official record
Conditions
Anemia, Anaemia
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Azusa, California • Glendale, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 27, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cold Water Exposure's Effects on Physical and Mental Health

NCT06667193
View directory record Official record
Conditions
Cold Exposure
Interventions
Cold Water Immersion (CWI) - Cold Tub Immersion (CI), Cold Water Immersion (CWI) - Cold Shower (CS)
Other
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Greeley, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 10:10 AM EDT
Active, not recruiting Not applicable Interventional

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

NCT04736121
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Interventions
Resin microspheres containing yttrium-90 (Y-90)
Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 27, 2026, 10:10 AM EDT
Completed Not applicable Interventional

Single-blind RCT Comparing Smartphone vs. Paper-based HEP in Pelvic Floor PT

NCT06162845
View directory record Official record
Conditions
Pelvic Floor Muscle Weakness
Interventions
A smartphone based application free to download from the google play and iphone store to provide auditory and visual cues and counting for number of perscribed pelvic floor muscle contractions, Paper-based home exercise program for pelvic floor muscle exercise
Behavioral
Lead sponsor
University of Central Arkansas
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 27, 2026, 10:10 AM EDT
Completed Early Phase 1 Interventional Results available

The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression

NCT02849639
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Placebo, Medication Therapy Management (MTM), Scopolamine patch
Other · Drug
Lead sponsor
Daniela Moga
Other
Eligibility
65 Years to 101 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 27, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hearing Program in Primary Care

NCT05943509
View directory record Official record
Conditions
Deafness
Interventions
Alternative rehabilitation strategies, Usual Care
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 10:10 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

NCT05055063
View directory record Official record
Conditions
Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 27, 2026, 10:10 AM EDT
Terminated Phase 1 Interventional

A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors

NCT00404521
View directory record Official record
Conditions
Solid Tumors
Interventions
PM02734
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 27, 2026, 10:10 AM EDT
Completed Phase 3 Interventional

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

NCT05774639
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab Injection, Xolair Prefilled Syringe
Drug
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 27, 2026, 10:10 AM EDT
Recruiting Phase 2 Interventional

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

NCT03907475
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Durvalumab, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 10:10 AM EDT
Recruiting Phase 2 Interventional

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

NCT07476001
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone cypionate (Tc), ADT with Luteinizing hormone-releasing hormone (LHRH) analog, PSMA-617
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 27, 2026, 10:10 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
The Bronx, New York • Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 10:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of an ADAPTive Intervention to Improve Food Security and Maternal-Child Health

NCT06942598
View directory record Official record
Conditions
Food Insecurity, Pregnancy
Interventions
Produce prescription, Medically tailored meals, Electronic health record WIC referral, Electronic health record WIC referral + care navigation
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

NCT02768701
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Pembrolizumab, Cyclophosphamide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chapel Hill, North Carolina • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 27, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide Chronotherapy for High Grade Glioma

NCT02781792
View directory record Official record
Conditions
Glioma, Glioblastoma Multiforme
Interventions
Temozolomide, Functional Assessment of Cancer Therapy - Brain, ActTrust Condor Instrument Watch
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 27, 2026, 10:10 AM EDT
Terminated Phase 2 Interventional Results available

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

NCT02663271
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
Interventions
Bevacizumab, Optune, Brain MRI, Quality of Life Questionnaires
Drug · Device · Other
Lead sponsor
University of Florida
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 27, 2026, 10:10 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).

NCT05906732
View directory record Official record
Conditions
Long QT Syndrome
Interventions
LQT-1213, Placebo, Dofetilide 250 μg Cap
Drug
Lead sponsor
Thryv Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 27, 2026, 10:10 AM EDT
Terminated Phase 2 Interventional

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

NCT02938793
View directory record Official record
Conditions
Cancer, Rare Disease
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 27, 2026, 10:10 AM EDT
Completed Not applicable Interventional Results available

Home-based Therapeutic Drug Monitoring in Kidney Transplantation

NCT05005221
View directory record Official record
Conditions
Kidney Transplant
Interventions
Automated text messages
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 27, 2026, 10:10 AM EDT
Recruiting Not applicable Interventional

Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

NCT06872684
View directory record Official record
Conditions
Aneurysm, Aneurysm, Intracranial
Interventions
Surpass Elite with Guardian Flow Diverter System
Device
Lead sponsor
Stryker Neurovascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
20
States / cities
Tucson, Arizona • Davis, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

NCT02927301
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
19
States / cities
Duarte, California • Santa Monica, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 10:10 AM EDT
Withdrawn Phase 2 Interventional

Single vs Multi-fraction SRS Patients on Immunotherapy

NCT04427228
View directory record Official record
Conditions
Brain Cancer, Brain Metastases
Interventions
Radiosurgery Single Treatment, Radiosurgery Three Treatments
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 27, 2026, 10:10 AM EDT
Completed Not applicable Interventional Results available

Genomic Sequencing for Childhood Risk and Newborn Illness

NCT02422511
View directory record Official record
Conditions
Hereditary Disease, Genetic Predisposition to Disease
Interventions
Genomic sequencing, Family history report
Genetic · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 27, 2026, 10:10 AM EDT
Recruiting Phase 2 Interventional

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

NCT06315309
View directory record Official record
Conditions
GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
ATG Combined with Tacrolimus and Mini Methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 27, 2026, 10:10 AM EDT